Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.
Maria C Katapodi, Valeria Viassolo, Maria Caiata-Zufferey...
https://pubmed.ncbi.nlm.nih.gov/28931501/Actively Recruiting
Led by University of Basel · Updated on 2026-05-13
700
Participants Needed
9
Research Sites
N/A
Total Duration
Researchers are studying hereditary breast and ovarian cancer HBOC and Lynch syndrome LS, which together account for about 30% of new cancer cases in Switzerland. The study focuses on genetic testing for these hereditary cancers to identify mutation carriers and improve prevention through early detection and management. Despite available genetic services, many mutation carriers and their family members do not use these services due to care coordination and communication challenges. The study uses a family-based cohort approach called CASCADE genetic screening, involving mutation carriers, their blood relatives who test negative, and untested relatives. It aims to survey index patients with HBOC or LS and their family members to understand their cancer status, genetic testing use, care coordination needs, communication patterns, and quality of life. The study will also explore the acceptability of a family-based communication and decision support intervention. Participants will be involved in surveys assessing their cancer and genetic mutation status, surveillance practices, psychosocial needs, communication with providers and family, and willingness to engage in genetic services. The primary outcome is establishing the CASCADE cohort within 12 months, with secondary outcomes including cancer surveillance practices. The study is observational and ongoing, with participants living in Switzerland and able to communicate in German, French, Italian, or English.
CONDITIONS
Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland
M
Maria C Katapodi, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Basel
Lead Sponsor
Kantonal Spital Solothurn, Olten
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - 12 months
Participants who undergo routine care are observed to establish the CASCADE Cohort and monitor cancer surveillance.
Assessments may occur periodically during the 12 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Maria C Katapodi, Valeria Viassolo, Maria Caiata-Zufferey...
https://pubmed.ncbi.nlm.nih.gov/28931501/Christos Nikolaidis, Chang Ming, Carla Pedrazzani...
https://pubmed.ncbi.nlm.nih.gov/30695780/University of Basel
Lead Sponsor
Kantonal Spital Solothurn, Olten
Collaborating Sponsor